ACUTE MYELOID LEUKEMIA

This study is testing a stem cell transplant from a partially matched family donor for patients with hard-to-treat blood cancers like leukemia and lymphoma. Before the transplant, patients receive chemotherapy and radiation to wipe out their own bone marrow and cancer cells. The …

This study is testing a new drug called CTX-712 for adults whose acute myeloid leukemia or myelodysplastic syndromes have returned or not responded to prior treatments. The main goals are to find a safe and effective dose and to see if the drug can help put the cancer into remiss…

This early-stage study aims to find the safest and most effective dose when combining two chemotherapy drugs, CPX-351 and gemtuzumab ozogamicin, to treat newly diagnosed acute myeloid leukemia (AML). Researchers will enroll up to 18 adult patients to test different dose levels an…

This study is testing a new, more intensive treatment plan for adults with aggressive blood cancers that are likely to return. The plan involves a combination of chemotherapy drugs and radiation, followed by a stem cell transplant from a donor. The goal is to see if this stronger…

This study is testing a new, lower-dose weekly schedule of two approved drugs (decitabine and venetoclax) for people with certain blood cancers like AML and MDS. The goal is to see if this gentler approach can control the cancer while causing fewer severe side effects and treatme…

This study is testing whether a drug called dexrazoxane can protect the heart from damage caused by powerful chemotherapy used to treat aggressive blood cancers like acute myeloid leukemia. It will enroll 100 patients with these cancers who are receiving a specific combination of…

This early-stage trial is testing a new drug called SEA-CD70, both alone and combined with other cancer medications, for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The main goal is to find safe doses and understand the side effects in adults whos…

This early-stage study is testing a new cell therapy for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have detectable cancer cells after initial treatment. Doctors collect a patient's own immune cells, modify them in a lab to better target …

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It is for older adults who are not candidates for standard intensive chemotherapy or for those whose disea…

This is a first-in-human study testing a new drug called STX-0712 in patients with advanced forms of blood cancer (CMML and AML) who have no remaining standard treatment options. The main goals are to find a safe dose and see if the drug shows any early signs of fighting the canc…

This early-stage trial is testing the safety of a modified donor stem cell transplant, called Orca-Q, for people with certain blood cancers like leukemia. The goal is to see if this engineered transplant can help patients recover their blood counts while reducing serious complica…

This study is testing a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) to see how well they work against aggressive forms of blood cancer, including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and chronic my…

This study is for older adults or those too frail for intensive chemotherapy who have a newly diagnosed, specific type of acute myeloid leukemia (AML) with an FLT3 mutation. It aims to see if adding a third drug, gilteritinib, to the standard two-drug treatment (azacitidine and v…

This early-stage study is testing a new drug called RPT1G in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have returned or not responded to standard treatments. The main goals are to find out if the drug is safe, what side effects i…

This early-stage study is testing a new type of stem cell transplant for adults aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The approach combines a precise form of radiation targeting bone marrow and lymph nodes with chemotherapy, followed by an infusion of…

This study is testing whether patients with acute myeloid leukemia (AML) who have responded well to venetoclax-azacitidine treatment can safely stop taking these drugs after 12 months while maintaining their remission. The trial will closely monitor 50 patients who stop treatment…

This study is testing a multi-step treatment for adults with newly diagnosed, higher-risk acute myeloid leukemia (AML). The goal is to use a combination of chemotherapy drugs to put the cancer into deep remission, followed by a stem cell transplant from a donor to try to keep it …

This study is testing if adding a drug called venetoclax to the standard pre-transplant chemotherapy improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 patients aged 12-60 will be randomly assigned to receive eit…

This early-phase study is testing a new, genetically modified T-cell therapy called SC-DARIC33 in children and young adults (up to age 30) whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe to make a…

This early-stage trial is testing whether combining three cancer drugs—iadademstat, venetoclax, and azacitidine—is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who haven't received treatment yet. The study aims to find the best dose of this comb…

This is the first-ever study in people for a new drug called GEN3018. It aims to find a safe and effective dose for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or is resistant to standard treatments. The main goals are to check the drug's safe…

This study is testing a refined procedure for umbilical cord blood transplants in adults and children with high-risk blood cancers like leukemia and lymphoma. The goal is to see if this optimized approach improves survival and reduces complications compared to standard transplant…

This early-stage study is testing the safety of a new cell therapy called Orca-T for adults with advanced blood cancers like leukemia. The goal is to see if combining Orca-T with two standard medications can reduce serious complications after a stem cell transplant from a partial…

This study is testing a new combination of three oral drugs for people with acute myeloid leukemia (AML). The first part aims to find the safest and most effective dose. The second part will see if that dose can help control the cancer in patients who are newly diagnosed but not …

This early-stage study is testing a new therapy that uses specially trained immune cells from a donor to try to prevent blood cancers from coming back after a stem cell transplant. The goal is to see if these 'memory-like' natural killer (NK) cells, given with a supporting drug, …

This study is testing a new combination of three drugs—ziftomenib, venetoclax, and gemtuzumab—for children and young adults whose acute myeloid leukemia has come back or hasn't responded to other treatments. The main goal is to find the safest and most effective dose of this comb…

This early-stage study aims to find a safe and effective dose of a new targeted drug, pivekimab sunirine, when given with a standard chemotherapy regimen (FLAG-Ida). It is for adults newly diagnosed with aggressive, high-risk blood cancers like acute myeloid leukemia (AML). The n…

This trial is testing whether adding two targeted drugs, midostaurin and gemtuzumab ozogamicin, to standard chemotherapy can better control a type of blood cancer called acute myeloid leukemia (AML). It is for adults newly diagnosed with AML who have specific genetic markers. The…

This is an early-stage study to find a safe dose of a new oral drug, HC-7366, for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Researchers will enroll about 18 participants to check for side effects and see if the drug shows …

This study is testing if adding a drug called venetoclax to a standard chemotherapy and stem cell transplant regimen works better for adults with high-risk forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see if this combination helps contro…

This study is testing a combination of three treatments for people whose acute myeloid leukemia (AML) has come back after a stem cell transplant. The goal is to see if the combination can control the disease and is safe for patients. It is for adults aged 18-60 who have relapsed …

This study is testing a new three-drug combination for adults with a specific type of acute myeloid leukemia (AML) who are too old or frail for standard intensive chemotherapy. The goal is to see if adding a drug called tagraxofusp to two existing drugs (venetoclax and azacitidin…

This early-stage study is testing a new oral drug called EP0042, both alone and combined with other cancer treatments, in adults with advanced blood cancers like acute myeloid leukemia (AML). The main goal is to find a safe and tolerable dose. The study is for patients whose canc…

This study is testing whether two oral medications, venetoclax and revumenib, can work together to eliminate minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who are in remission. MRD refers to a small number of cancer cells that remain after treatment…

This early-stage study is testing the safety and initial effectiveness of adding a new drug, FHD-286, to a standard two-drug treatment for acute myeloid leukemia (AML). It is for adults with newly diagnosed high-risk AML or AML that has come back after one prior treatment. The ma…

This study aims to find better treatments for children and young adults whose leukemia has returned or is hard to treat. It screens patients' blood and bone marrow to understand their specific cancer and match them to new, targeted therapy trials. The goal is to control the disea…

This early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…

This study is testing a new combination of three oral drugs (ASTX727, venetoclax, and gilteritinib) for adults with specific types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have a genetic change called an FLT3 mutation. The first part aims t…

This study is testing whether a new three-drug combination called ABC-14 works better than current standard treatments for adults newly diagnosed with acute myeloid leukemia (AML), a serious blood cancer. Researchers will compare ABC-14 against the traditional "3+7" chemotherapy …

This study is testing a new treatment for adults and teens whose blood cancers like leukemia have come back after a stem cell transplant. The treatment involves giving patients special immune cells, called CIML NK cells, from their original transplant donor, along with a drug cal…

This study is testing if adding a pill called venetoclax to standard chemotherapy helps children and young adults whose acute myeloid leukemia (AML) has come back. It's for patients aged 29 days to 21 years whose cancer has relapsed once or twice. The main goal is to see if this …

This early-stage study is testing a new type of CAR T-cell therapy called ADCLEC.syn1 in adults whose acute myeloid leukemia has returned or hasn't responded to standard treatments. The main goal is to find the highest dose that is safe and causes only mild side effects. Once a s…

This study is testing a targeted drug called enasidenib, sometimes combined with another drug (azacitidine), for people with a high-risk type of blood and bone marrow disorder called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to…

This is a first-in-human study to test the safety of a new type of immune cell therapy for adults with acute myeloid leukemia (AML). Researchers will give patients specially trained 'memory-like' natural killer (NK) cells along with a standard drug called venetoclax, aiming to be…

This study tests whether adding the drug ruxolitinib to two standard medications helps prevent graft-versus-host disease (GVHD) in children and young adults receiving bone marrow transplants for blood cancers. GVHD is a serious complication where donor immune cells attack the pat…

This study is testing whether a three-drug combination followed by ongoing maintenance therapy can effectively treat and prevent relapse in older adults with a specific type of acute myeloid leukemia (AML). Researchers want to see if this approach keeps the cancer from returning …

This study is testing whether giving blood transfusions at a lower hemoglobin level (7 gm/dL) works as well as giving them at a higher level (9 gm/dL) for leukemia patients after chemotherapy or stem cell transplant. Researchers want to see if the lower level maintains patients' …

This early-stage study is testing the safety of a new drug, SL-401, when combined with standard medications for certain aggressive blood cancers. It aims to find the highest safe dose for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic plasm…

This early-stage study is testing a new drug called bleximenib in people with acute leukemia that has come back or not responded to other treatments. The first goal is to find a safe and effective dose. The second goal is to see if this dose can help patients achieve remission, w…

This study is testing if a weekly injection called Romiplostim N01 can help platelets recover faster after a stem cell transplant for blood cancers like leukemia. About 130 patients will be randomly assigned to receive either the new drug or standard care, and researchers will tr…

This early-stage trial is testing whether adding a healthy donor's natural killer (NK) immune cells to two standard leukemia drugs can help control acute myeloid leukemia (AML). The study will enroll 32 adults with AML that has returned or not responded to prior treatment, or old…

This large, late-stage trial is testing whether adding a new oral drug called APG-2575 (lisaftoclax) to a standard treatment (azacitidine) helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study will enroll about 486 patients worldwide who are …

This trial is testing whether a drug called quizartinib can help prevent a specific type of acute myeloid leukemia (AML) from coming back. It is for adults whose cancer is in remission after initial treatment but who have not had a stem cell transplant. The study will compare two…

This study is testing new drug combinations for children and young adults newly diagnosed with a serious blood cancer called acute myeloid leukemia (AML). It aims to see if a newer, packaged chemotherapy (CPX-351) works better and is safer for the heart than standard chemotherapy…

This early-stage study is testing whether combining two oral drugs, revumenib and mezigdomide, is safe and effective for people with specific types of acute leukemia that have returned or not responded to prior treatments. The trial will enroll about 52 participants aged 12 and o…

This study is testing a new oral drug called revumenib to see if it can safely help prevent certain aggressive types of leukemia from coming back after a patient has received a stem cell transplant. The trial will enroll about 27 patients, including children as young as 2, who ha…

This study is testing a new combination of targeted drugs for people with advanced blood cancers that have a specific genetic change called an IDH1 mutation. The main goals are to find the safest dose and see how well the drug combo works to control the cancer. The trial is for a…

This early-stage study is testing whether adding an experimental drug called ziftomenib to standard care after a bone marrow transplant is safe and can help keep acute myeloid leukemia (AML) from coming back. The study will enroll about 22 adults with specific genetic types of AM…

This study is testing a modified, two-step stem cell transplant procedure designed to be safer. It aims to reduce deaths caused by the transplant treatment itself in patients with various blood cancers and disorders. The trial compares two gentler preparation methods using lower …

This large, late-stage trial aims to find out if newer, gentler personalized treatments work as well as or better than strong chemotherapy for adults whose acute myeloid leukemia (AML) has returned or hasn't responded to initial treatment. It will directly compare these two appro…

This study is testing a combination of two drugs, CPX-351 and quizartinib, to see if they can help control acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The main goals are to find the safest and most effective dose and to see how well the treatment wo…

This study aims to see if a newer drug combination (venetoclax + azacitidine) works as well as or better than standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer. About 172 participants will be randomly assigned to recei…

This trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 fo…

This early-stage study is testing a new cell therapy for adults with certain blood cancers who have received a bone marrow transplant from a partially matched family donor. Researchers take a special type of the patient's own immune cells, grow and activate them in a lab, and the…

This study is testing a new treatment combination for adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). The goal is to see if a regimen based on the drug venetoclax, which avoids harsh traditional chemotherapy drugs called anthracyclines, can ef…

This early-stage study is testing the safety and initial effectiveness of a new drug, rezatapopt, combined with an existing drug, azacitidine, for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The trial is specifically for patients whose cancer has a…

This study is testing a new experimental drug that delivers radiation directly to cancer cells in patients with high-risk blood cancers like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The goal is to find the safest and most effective dose of this targete…

This early-stage study is testing the safety and best dose of a drug called venetoclax when added to standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). The goal is to see if this combination can better co…

This study aims to find a safe and effective dose of a two-drug combination (venetoclax and ASTX727) for children and teenagers whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It will enroll up to 40 participants aged 2 to 18 years old. The main…

This early-stage study is testing the safety and feasibility of using bone marrow from deceased donors for patients with various blood cancers like leukemia and lymphoma. The goal is to see if this type of transplant can help patients when a living donor isn't available. Research…

This early-stage trial is testing a new combination of three drugs for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to other treatments. The goal is to find the safest and most effective dose by combining an immunot…

This study is testing a new method to help patients recover their immune systems faster after a stem cell transplant for leukemia. It involves giving patients a special, filtered portion of their donor's immune cells, aiming to reduce the risk of life-threatening viral and fungal…

This early-stage trial is testing the safety and best dose of a new two-drug oral combination (ziftomenib + quizartinib) for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The main goal is to see if the combinati…

This study tests whether the drug DASATINIB can help adults with acute myeloid leukemia when standard treatments have failed. Researchers will give 35 participants DASATINIB for up to 3 months and monitor their blood and bone marrow response. The goal is to see if this approach c…

This is the first study in people to test a new oral medication called GLB-001. It aims to find a safe and effective dose for adults with advanced forms of acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to other treatments. The main goals …

This study is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and effective. It will involve 420 adults with acute myeloid leukemia (AML) who have specific genetic changes in their cancer cells. The main goals are to find the …

This early-stage study is testing a new drug called BGB-11417, both by itself and combined with an existing drug (azacitidine), for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The main goals are to find a safe and effec…

This study is testing whether a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) can help control acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. It will involve 68 patients aged 16-70 to see if this new comb…

This is the first time a new drug called ziftomenib is being tested in people. The study aims to find a safe and effective dose for adults with advanced acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has returned or not responded to other treatments. It w…

This study tests whether a combination of two drugs (venetoclax and azacitidine) can eliminate tiny amounts of remaining leukemia cells in patients with acute myeloid leukemia (AML). It's for adults who still have detectable cancer cells after their initial chemotherapy or right …

This study is testing a new oral medication called revumenib for people with acute leukemias that have come back or not responded to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will test how well the drug works…

This study is testing a new three-drug combination (tagraxofusp, azacitidine, and venetoclax) for adults newly diagnosed with a specific, aggressive form of acute myeloid leukemia (AML) that developed after their previous blood disorder treatment stopped working. The main goal is…

This study is testing a new oral pill called ASTX030 for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The main goal is to see if the pill works as well as or better than the standard injected medication. It will also tes…

This study is testing a new combination of cancer drugs for adults with aggressive forms of acute myeloid leukemia (AML) and related blood cancers that are newly diagnosed as high-risk or have come back after previous treatment. The goal is to find the safest and most effective d…

This early-stage trial is testing a new drug called BMS-986497 for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or resisted previous treatments. Researchers will give the drug alone and in combination with two standard cancer medications to fin…

This study is testing whether giving a maintenance drug after standard treatment can help keep favorable-risk acute myeloid leukemia (AML) in remission longer and improve survival. It will involve about 77 patients who have already achieved remission with initial therapy and have…

This study is testing a new treatment for acute myeloid leukemia (AML) that has come back or hasn't responded to standard chemotherapy. Doctors take immune cells (called natural killer cells) from a partially matched family donor, boost them in the lab to create a 'memory-like' s…

This study is testing whether adding a drug called chidamide to a standard two-drug leukemia treatment can help patients who didn't respond well enough to the standard treatment alone. It is for adults with acute myeloid leukemia (AML) who are older or cannot tolerate strong chem…

This study is testing a drug called olutasidenib as a long-term 'maintenance' therapy for adults with a specific genetic form of acute myeloid leukemia (AML). The goal is to see if taking this pill for up to two years after finishing standard chemotherapy is safe and can help kee…

This study is testing the safety of a new type of stem cell transplant for children whose cancers have come back or are very hard to treat. Doctors use a half-matched family donor and a special process to remove certain immune cells from the transplant, aiming to reduce complicat…

This study is testing a new treatment plan for adults with a specific genetic type of acute myeloid leukemia (AML). The goal is to see if a combination of targeted drugs and chemotherapy can control the cancer so well that a risky stem cell transplant might be avoided. Researcher…

This is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for patients with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The therapy involves modifying a patient's own immune cells to tar…

This early-stage trial is testing a new drug called Debio 1562M for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The study aims to find a safe dose and see if the drug can reduce or eliminate leukemia cells. Participants will…

This early-stage study is testing whether a two-drug combination is safe and can help prevent cancer from coming back in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after they receive a stem cell transplant from a donor. The treatment involves tag…

This study is testing whether combining four different cancer drugs works better than current treatments for adults with newly diagnosed acute myeloid leukemia (AML), a fast-growing blood cancer. About 145 participants will receive the drug combination in cycles to try to elimina…

This is an early safety study for adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. Researchers are testing a new combination of two drugs, bomedemstat and venetoclax, to find the safest dose and see if the body can tolerate them. The…

This is a first-in-human study to find a safe dose of a new drug called cirtuvivint for patients with advanced forms of blood cancer. The trial will test cirtuvivint by itself in patients whose cancer has returned or resisted treatment, and also test it combined with an existing …

This early-stage trial is testing whether taking oral medications can help keep acute myeloid leukemia (AML) from returning after patients achieve remission. The study will enroll 125 adults with AML who have responded to initial treatment but aren't candidates for stem cell tran…

This large study is testing if adding a drug called venetoclax to standard intensive chemotherapy helps adults newly diagnosed with acute myeloid leukemia (AML) live longer without their cancer returning. About 650 participants will be randomly assigned to receive either the real…

This study is testing a combination of three drugs (olutasidenib, venetoclax, and azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukemia (AML) that has an IDH1 mutation. The main goals are to see if this combination is safer and works better than t…

This study is testing a new immune cell therapy for children and young adults (up to age 40) with high-risk acute myeloid leukemia (AML). The goal is to see if giving specially prepared 'memory-like' natural killer (NK) cells from a partially matched family donor is safe and poss…

This is the first-ever study in people of an experimental treatment called CER-1236 for acute myeloid leukemia (AML) that has come back or is resistant to other treatments. Doctors will test the safety and early effectiveness of this therapy, which uses a patient's own immune cel…

This study is testing a drug called ponatinib in children and teenagers (ages 1 to 18) whose cancers have come back or have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help control various advanced cancers, including leukem…

This study is testing a two-part treatment for people whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back after a stem cell transplant. The treatment combines an immune-boosting drug (interferon-gamma) with an infusion of cells from the original tra…

This study aims to see if a genetic test can help doctors decide which leukemia patients should receive a stronger antifungal drug to prevent dangerous mold infections during chemotherapy. About 410 adults with acute myeloid leukemia will be tested for a specific genetic marker. …

This study is for older adults (or younger adults unfit for standard chemo) newly diagnosed with a specific type of acute myeloid leukemia (AML) caused by a change in the IDH2 gene. It compares two oral drug combinations to see if adding a third drug, enasidenib, helps more patie…

This study is for people with acute leukemia or myelodysplastic syndrome (MDS) who need a stem cell transplant from a donor. The main goal is to find the best way to reduce a serious complication called graft-versus-host disease (GVHD), where the donor's immune cells attack the p…

This study is testing whether a two-drug treatment given after a bone marrow transplant can help prevent leukemia and related blood cancers from coming back. It involves children and young adults up to age 39 who have had a transplant for conditions like acute myeloid leukemia (A…

This study is testing which of two drug regimens works better to prepare high-risk or relapsed acute leukemia patients for a stem cell transplant. Researchers will compare a new combination called TmBU against a standard modified Bu/Cy regimen. The main goal is to see which appro…

This early-stage study is testing a new drug called CCS1477 (inobrodib) in patients with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and if it shows signs of …

This early-stage trial is testing the safety and proper dosing of an experimental oral medication called MRX-2843. It is for adolescents and adults whose acute leukemia has come back or has not responded to previous treatments. The main goal is to find the highest dose that can b…

This study is testing five different drug combinations to see which works best for adults under 60 with high-risk acute myeloid leukemia (AML), a fast-growing blood cancer that's hard to treat. Participants are randomly assigned to receive either the standard chemotherapy or one …

This study is testing whether swapping two specific chemotherapy cycles in the standard treatment for children with acute myeloid leukemia (AML) is safe and tolerable. The goal is to achieve similar or better survival rates while potentially reducing the risk of severe long-term …

This early-stage study aims to find the safest dose of a new two-drug combination for people with high-risk myelodysplastic syndromes (MDS) and certain types of leukemia. The trial combines an approved tablet with an experimental drug to try to better control these serious blood …

This study is testing a new therapy for children and young adults with acute leukemia that has not responded well to standard chemotherapy. The treatment involves giving patients special immune cells, called NK cells, from a donor before and after a stem cell transplant. The main…

This study is testing a combination of two drugs, venetoclax and azacitidine, for adults in India newly diagnosed with an aggressive blood cancer called acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy. The main goals are to see how well the t…

This study tests whether a drug combination can help control acute myeloid leukemia (AML) in patients with a specific genetic mutation (IDH1) who have already received standard treatment. The trial involves 28 adults who responded to prior therapy but need additional treatment. P…

This study is for younger adults (18-59) newly diagnosed with a specific intermediate-risk type of acute myeloid leukemia (AML), a blood and bone marrow cancer. It compares three different drug combinations to see if adding a newer drug called venetoclax to standard chemotherapy …

This study aims to monitor the safety and effectiveness of the drug Mylotarg in adults newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML). It will observe 165 patients in Korea who are already receiving Mylotarg as part of their standard hospital care…

This study is testing whether a combination of two drugs, cladribine and venetoclax, can help control acute myeloid leukemia (AML) in adults when a similar previous treatment has stopped working. The trial is for people whose AML has a specific pattern (monocytic) and has come ba…

This trial is testing whether a combination of chemotherapy and targeted drugs can better prepare patients with advanced blood cancers for a stem cell transplant. The goal is to control the aggressive cancer enough so patients can safely receive donor stem cells, which may offer …

This early-stage study is testing a new type of personalized cell therapy for adults with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatments. Doctors take immune cells from a donor, genetically modify them in a lab to better recognize and…

This early-stage trial is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and tolerable for patients. It focuses on adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy and has specific …

This early-stage study is testing if adding a new oral drug called pemigatinib after standard chemotherapy is safe and helpful for adults newly diagnosed with a higher-risk form of acute myeloid leukemia (AML). The goal is to see if blocking a specific growth signal in cancer cel…

This early-stage trial is testing whether combining a new drug called 8-chloroadenosine with an existing cancer drug (venetoclax) is safe and tolerable for adults with acute myeloid leukemia that has come back or stopped responding to other treatments. The main goal is to find th…

This study is testing a new type of stem cell transplant for children and young adults with serious blood cancers like leukemia. The transplant uses donor cells that have been specially prepared in a lab. Researchers want to see if this new method is safe and can help patients re…

This early-stage study is testing the safety and initial effectiveness of a new drug called Danvatirsen, first by itself and then combined with an existing drug, Venetoclax. It is for adults with advanced forms of blood cancer (MDS or AML) that have returned or not responded to a…

This study is testing whether an oral medication can help prevent relapse in acute myeloid leukemia patients who are eligible for a stem cell transplant but cannot get one due to social or economic barriers. It will enroll 12 adult patients who have achieved remission but face ch…

This early-stage study is testing whether giving specially grown immune cells from a stem cell donor can help prevent cancer from coming back after a transplant for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to see if this approach is safe a…

This early-stage study is testing a new cell therapy called CD4CAR for adults and teens with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to target the cancer, and infuse th…

This trial is testing whether a targeted drug called gemtuzumab ozogamicin can eliminate hidden cancer cells in adults with acute myeloid leukemia (AML) who are in remission but still have measurable residual disease. The drug works like a guided missile—it attaches to specific m…

This study is testing whether adults with newly diagnosed acute myeloid leukemia (AML) who have achieved deep remission can safely stop their chemotherapy for a period after one year of treatment. Researchers want to see if taking a break from treatment reduces side effects while…

This early-stage trial is testing if adding two anti-cancer drugs, decitabine and venetoclax, to a standard stem cell transplant procedure is safe for adults with high-risk blood cancers like acute myeloid leukemia (AML). The main goal is to find the safest dose and see if this c…

This early-stage trial is testing whether a drug called olutasidenib can safely prevent certain blood cancers from returning after a patient has received a donor bone marrow transplant. The study will enroll about 15 adults with acute myeloid leukemia, myelodysplastic syndrome, o…

This study is testing whether adding a targeted drug called venetoclax to a standard chemotherapy regimen works better than the current standard treatment for newly diagnosed acute myeloid leukemia (AML). It will involve about 102 adults and aims to see if the new combination lea…

This study is testing a new, faster treatment plan for adults aged 60 and older with aggressive blood cancers like acute myeloid leukemia (AML). The goal is to see if giving strong chemotherapy followed quickly by a lower-intensity stem cell transplant is safer and more effective…

This study is testing a combination of three oral medications for adults with acute myeloid leukemia (AML) that has come back or not responded to prior treatment. The goal is to see if this new combination is safe and can help control the cancer. The trial will enroll about 84 pa…

This early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…

This is a first-in-human study to check the safety of a new three-drug combination (Q702, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The main goal is to find a safe dose and see what side effec…

This study aims to collect blood and tissue samples to help develop a single blood test that can detect many different cancers early. Researchers will enroll 2,000 people, including those with cancer and those without, to create a reference set for testing. The goal is to validat…

This early-stage trial is testing a new vaccine designed to prevent serious cytomegalovirus (CMV) infections. The study involves patients with blood cancers who are receiving a stem cell transplant from a partially matched donor, a procedure that carries a high risk of CMV. Resea…

This study is testing a new vaccine approach to prevent a common and serious viral infection called CMV in patients receiving a stem cell transplant for blood cancers. Researchers are giving the vaccine to the healthy stem cell donors, hoping the donor's boosted immunity will be …

This study is testing whether a long-acting antibiotic called dalbavancin, given every 28 days, can prevent serious bloodstream infections in children and young adults with high-risk leukemia who are receiving intense chemotherapy. The trial will enroll up to 29 participants to s…

This study is testing whether providing financial guidance to people with acute myeloid leukemia (AML) can reduce the money-related stress of cancer treatment and improve their overall health and quality of life. It will enroll 120 adults who are starting intensive chemotherapy. …

This study is testing whether a telehealth program helps older patients with serious blood cancers have better conversations with their doctors about future care wishes. It aims to see if these structured video calls reduce patient anxiety and distress, and help more people compl…

This study is testing if a widely available, inexpensive drug called tranexamic acid can safely reduce bleeding episodes in outpatients with serious blood cancers (MDS or AML). About 75 adult patients with low platelet counts will be randomly assigned to receive either the drug o…

This study is testing whether cancer patients with low blood counts can safely receive blood transfusions at home instead of at the hospital. Researchers will enroll 30 patients who regularly need blood transfusions and give them 1-5 transfusions at home. The main goal is to see …

This early-stage study aims to understand how a cancer drug is processed by the body in patients with moderate to severe liver problems. It will enroll about 27 adults with certain blood cancers or solid tumors to measure drug levels and check for side effects. The main goal is t…

This study is testing a new laboratory method to detect very small numbers of leftover leukemia cells in the blood and bone marrow of children. The goal is to better predict which children are at high risk of their cancer coming back after initial treatment. If successful, this c…

This study is testing a new type of imaging scan to see if it can find leftover cancer cells in people with leukemia or myeloma. Researchers want to know if the scan results match up with other standard lab tests. The goal is to see if this scan could one day help doctors better …

This early-stage study aims to understand how a combination cancer pill is processed by the body in patients with severe kidney problems compared to those with normal kidney function. It will enroll about 18 adults with certain blood cancers or solid tumors who could benefit from…

This study aims to understand if a targeted radiation therapy for neuroendocrine tumors (PRRT) increases the risk of patients later developing serious blood cancers like myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Researchers will collect and analyze blood sam…

This study is a large screening program designed to help match adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to the most appropriate treatment study within the national MyeloMATCH network. It involves testing a patient's bone marrow and blood for spec…

This early-stage study aims to understand how the body absorbs, breaks down, and eliminates the experimental drug bleximenib in people with acute leukemia. Researchers will give a small, traceable radioactive version of the drug to 10 participants with specific types of advanced …

This study is developing more sensitive blood tests to find tiny amounts of hidden cancer cells that remain after treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers want to see if these tests can identify patients who are at higher risk of t…

This study aims to understand how the amount of the leukemia drug venetoclax in a patient's blood relates to how well the treatment works and its side effects. It will observe 100 adults with acute myeloid leukemia who are starting standard treatment with venetoclax and azacitidi…

This study aims to understand how the immune system changes in acute myeloid leukemia (AML) patients who receive a stem cell transplant. Researchers will collect blood samples from 250 patients before and after their transplant to analyze immune cells. The goal is to learn if the…

This study is testing a new, detailed genetic test called ChromoSeq for patients with blood cancers AML or MDS. Researchers want to see if this test, which looks at a person's entire genetic code, finds more cancer-related changes than current standard tests. They will enroll 325…

This study aims to learn how radiation and chemotherapy affect the bone marrow of people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples from about 74 adult participants at different times during their treatment. The goal is to ga…

This study aims to gather detailed information on many different blood diseases in China, including cancers like leukemia and lymphoma, and conditions like hemophilia. It will follow 2,300 patients to learn how common these diseases are, what treatments patients receive, how well…

This study aims to understand how the immune system changes when patients with acute myeloid leukemia (AML) receive standard chemotherapy. Researchers will collect blood and bone marrow samples from 80 adults receiving treatment to analyze their immune profiles. The goal is to ga…

This study is collecting tissue and blood samples from cancer patients over time to create a research resource called a biobank. Researchers will analyze these samples to understand how cancer changes during treatment and why some treatments stop working. The goal is to help scie…

This study aims to understand how chemotherapy affects memory, concentration, and thinking skills in people being treated for blood cancers like leukemia and lymphoma. Researchers will compare 120 cancer patients to a control group of their relatives, using questionnaires and thi…

This study aims to understand how inherited changes in certain genes, especially the DDX41 gene, increase a person's risk of developing blood cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Researchers will follow over 500 participants, including peo…